GlassScriptPhysician profile
Tin T Hla
NPI 1326098179
$6,651.90
in general payments reported to CMS, 2019-2025
41 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,374 · 2020: $647 · 2021: $1,014 · 2022: $1,004 · 2023: $545 · 2024: $332 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525 · Education: $87.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.36 |
| Education | $87.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $672.62 | 2019-2024 | Darzalex, Tecvayli, Talvey |
| Novartis Pharmaceuticals Corporation | $651.68 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $559.55 | 2019-2025 | Opdivo |
| Pfizer INC. | $453.19 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $445.18 | 2019-2025 | Tagrisso, Imfinzi, Calquence |
| Lilly USA, LLC | $441.41 | 2019-2025 | Jaypirca, Verzenio |
| Astellas Pharma US INC | $349.66 | 2019-2025 | Padcev, Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $325.44 | 2019-2025 | Advate |
| Merck Sharp & Dohme LLC | $279.69 | 2019-2025 | Keytruda, Welireg |
| Glaxosmithkline, LLC. | $236.45 | 2020-2025 | Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $225.71 | 2019-2023 | |
| Eisai INC. | $153.30 | 2019-2025 | |
| Genentech USA, INC. | $146.20 | 2019-2020 | |
| Celgene Corporation | $140.98 | 2019-2022 | |
| Seagen INC. | $133.31 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tin Hla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.